

## AUTHOR INDEX

- Abrams, S.I., 672  
 Aisenberg, A.C., 251  
 Akhurst, T., 577  
 Ansell, S.M., 316  
  
 Baar, J., 270  
 Babaian, R.J., 140  
 Bangma, C.H., 422  
 Beedassy, A., 428  
 Bekradda, M., 647  
 Bertino, J.R., 606  
 Blanke, C.D., 632  
 Brito, R., 640  
 Brogi, E., 357  
 Bruckmeier, E.M., 382  
 Buchele, T., 589  
 Burkes, R.L., 270  
 Byrd, J.C., 48  
  
 Cao, S., 612  
 Cardi, G., 428  
 Cohen, A.M., 505  
 Crawford, E.D., 162  
 Crump, M., 324  
 Cvitkovic, E., 647  
  
 Dagleish, A.G., 455  
 Daliani, D., 399  
 Danenberg, P.V., 621  
 Dannenberg, A.J., 499  
 Dawson, N.A., 174  
 Dempke, W., 589  
 DeVita, V.T.Jr., 67  
 Doll, D.C., 249, 259  
  
 Edenfield, W.J., 21  
  
 Fein, S., 192  
 Fine, H.A., 346  
 Finiewicz, K.J., 6  
 Flynn, J.M., 48  
 Fong, Y., 514  
  
 Gilliam, A.C., 290  
 Gjersten, B.T., 382  
 Gomella, L.G., 439  
 Gore, S.D., 21  
 Gorlick, R., 606  
 Gospodarowicz, M., 270, 324  
 Gotkas, S., 162  
 Grant, C.S., 316  
 Greiner, J., 672  
 Grothey, A., 589  
 Guillem, J.G., 505  
  
 Habermann, T.M., 307, 316  
 Haller, D.G., 545  
  
 Harris, D.T., 439  
 Harris, N.L., 357  
 Herrin, V.E., 99  
 Hodge, J.W., 672  
 Hoff, P.M., 640  
 Hope, R.T., 276  
 Hrouda, D., 455  
 Hudis, C.A., 35  
 Hwang, L.C., 192  
  
 Inwards, D.J., 307  
  
 Jacobs, C., 338  
 Jenster, G., 407  
  
 Kamoi, K., 140  
 Kamrtdt, J.M., 234  
 Kantor, J.A., 672  
 Kemeny, N.E., 475, 524  
 Kemeny, N.E., 587  
 Kim, Y.H., 276  
 Kurtin, P.J., 307  
 Kyle, R.A., 74  
  
 Larson, R.A., 6  
 Larson, S.M., 577  
 Levitsky, H., 192  
 Lin, S-H., 227  
 Lofgren, J.A., (s)60  
 Logothetis, C.J., 139, 369  
 Lynch, H.T., 478  
  
 Macdonald, J.S., 556  
 Maher, E.A., 346  
 Makower, D., 663  
 Malli, H., 621  
 Markman, M., 536  
 Markowitz, A.J., 485  
 Marshall, N.A., 67  
 Mastrangelo, M.J., 439  
 Matyas, G.R., 439  
 McDonell, T.J., 382  
 Medgyesy, D., 640  
 Millikan, R.E., 185  
 Minsky, B.D., 540  
 Moore, H.C.F., 545  
 Morrison, V.A., 84  
 Munster, P.N., 35  
 Myers, R.E., 375  
  
 Nasu, Y., 422  
 Nelson, W.G., 192  
 Norton, L., (s)78  
  
 Papandreou, C.N., 399  
 Pazdur, R., 640  
 Perry, M., 455  
  
 Peterson, B.A., 84  
 Pienta, K.J., 234  
 Pisters, L.L., 202  
 Pollack, A., 150  
 Pu, Y-S., 227  
  
 Ren, C., 422  
 Ripple, G.H., 217  
 Ritter, G., 683  
 Ron, I.G., 524  
 Rosen, I.I., 150  
 Rothenberg, M.L., 632  
 Royce, M., 640  
 Rustum, Y.M., 612  
 Ryu, J.H., 307  
  
 Salo, J., 514  
 Scher, H.I., 448  
 Schlom, J., 672  
 Schmoll, H.J., 589  
 Schrag, D., 561  
 Schwartz, L.H., 569  
 Seidman, A.D., (s)78  
 Seynaeve, C., 119  
 Shabab, N., 259  
 Shak, S., (s)71  
 Shepherd, F.A., 324  
 Slovin, S.F., 448  
 Smyrk, T.C., 478  
 Sobecks, R.M., 106  
 Spitler, L.E., 439  
 Sprangers, M.A.G., 691  
 Swenson, S., 621  
 Szatrowski, T.P., 62  
  
 Talor, E., 439  
 Thigpen, J.T., 99  
 Thompson, T.C., 422  
 Tsang, K-Y., 672  
  
 Verweij, J., 119  
 Vogelzang, N.J., 106  
  
 Wadler, S., 663  
 Waselenko, J.K., 48  
 Weeks, J., 561  
 Weiss, R.B., 1  
 Welt, S., 683  
 Wilding, G., 217  
 Winawer, S.J., 485  
 Winship, M.D., 439  
 Wood, G.S., 290  
  
 Yuen, A., 338  
  
 Zagars, G.K., 150  
 Zakim, D., 499  
 Zaremba, S., 672

## AUTHOR INDEX

- Abrams, S.I., 672  
 Aisenberg, A.C., 251  
 Akhurst, T., 577  
 Ansell, S.M., 316  
  
 Baar, J., 270  
 Babaian, R.J., 140  
 Bangma, C.H., 422  
 Beedassy, A., 428  
 Bekradda, M., 647  
 Bertino, J.R., 606  
 Blanke, C.D., 632  
 Brito, R., 640  
 Brogi, E., 357  
 Bruckmeier, E.M., 382  
 Buchele, T., 589  
 Burkes, R.L., 270  
 Byrd, J.C., 48  
  
 Cao, S., 612  
 Cardi, G., 428  
 Cohen, A.M., 505  
 Crawford, E.D., 162  
 Crump, M., 324  
 Cvitkovic, E., 647  
  
 Dagleish, A.G., 455  
 Daliani, D., 399  
 Danenberg, P.V., 621  
 Dannenberg, A.J., 499  
 Dawson, N.A., 174  
 Dempke, W., 589  
 DeVita, V.T.Jr., 67  
 Doll, D.C., 249, 259  
  
 Edenfield, W.J., 21  
  
 Fein, S., 192  
 Fine, H.A., 346  
 Finiewicz, K.J., 6  
 Flynn, J.M., 48  
 Fong, Y., 514  
  
 Gilliam, A.C., 290  
 Gjersten, B.T., 382  
 Gomella, L.G., 439  
 Gore, S.D., 21  
 Gorlick, R., 606  
 Gospodarowicz, M., 270, 324  
 Gotkas, S., 162  
 Grant, C.S., 316  
 Greiner, J., 672  
 Grothey, A., 589  
 Guillem, J.G., 505  
  
 Habermann, T.M., 307, 316  
 Haller, D.G., 545  
  
 Harris, D.T., 439  
 Harris, N.L., 357  
 Herrin, V.E., 99  
 Hodge, J.W., 672  
 Hoff, P.M., 640  
 Hope, R.T., 276  
 Hrouda, D., 455  
 Hudis, C.A., 35  
 Hwang, L.C., 192  
  
 Inwards, D.J., 307  
  
 Jacobs, C., 338  
 Jenster, G., 407  
  
 Kamoi, K., 140  
 Kamrtdt, J.M., 234  
 Kantor, J.A., 672  
 Kemeny, N.E., 475, 524  
 Kemeny, N.E., 587  
 Kim, Y.H., 276  
 Kurtin, P.J., 307  
 Kyle, R.A., 74  
  
 Larson, R.A., 6  
 Larson, S.M., 577  
 Levitsky, H., 192  
 Lin, S-H., 227  
 Lofgren, J.A., (s)60  
 Logothetis, C.J., 139, 369  
 Lynch, H.T., 478  
  
 Macdonald, J.S., 556  
 Maher, E.A., 346  
 Makower, D., 663  
 Malli, H., 621  
 Markman, M., 536  
 Markowitz, A.J., 485  
 Marshall, N.A., 67  
 Mastrangelo, M.J., 439  
 Matyas, G.R., 439  
 McDonell, T.J., 382  
 Medgyesy, D., 640  
 Millikan, R.E., 185  
 Minsky, B.D., 540  
 Moore, H.C.F., 545  
 Morrison, V.A., 84  
 Munster, P.N., 35  
 Myers, R.E., 375  
  
 Nasu, Y., 422  
 Nelson, W.G., 192  
 Norton, L., (s)78  
  
 Papandreou, C.N., 399  
 Pazdur, R., 640  
 Perry, M., 455  
  
 Peterson, B.A., 84  
 Pienta, K.J., 234  
 Pisters, L.L., 202  
 Pollack, A., 150  
 Pu, Y-S., 227  
  
 Ren, C., 422  
 Ripple, G.H., 217  
 Ritter, G., 683  
 Ron, I.G., 524  
 Rosen, I.I., 150  
 Rothenberg, M.L., 632  
 Royce, M., 640  
 Rustum, Y.M., 612  
 Ryu, J.H., 307  
  
 Salo, J., 514  
 Scher, H.I., 448  
 Schlom, J., 672  
 Schmoll, H.J., 589  
 Schrag, D., 561  
 Schwartz, L.H., 569  
 Seidman, A.D., (s)78  
 Seynaeve, C., 119  
 Shabab, N., 259  
 Shak, S., (s)71  
 Shepherd, F.A., 324  
 Slovin, S.F., 448  
 Smyrk, T.C., 478  
 Sobecks, R.M., 106  
 Spitler, L.E., 439  
 Sprangers, M.A.G., 691  
 Swenson, S., 621  
 Szatrowski, T.P., 62  
  
 Talor, E., 439  
 Thigpen, J.T., 99  
 Thompson, T.C., 422  
 Tsang, K-Y., 672  
  
 Verweij, J., 119  
 Vogelzang, N.J., 106  
  
 Wadler, S., 663  
 Waselenko, J.K., 48  
 Weeks, J., 561  
 Weiss, R.B., 1  
 Welt, S., 683  
 Wilding, G., 217  
 Winawer, S.J., 485  
 Winship, M.D., 439  
 Wood, G.S., 290  
  
 Yuen, A., 338  
  
 Zagars, G.K., 150  
 Zakim, D., 499  
 Zaremba, S., 672

## SUBJECT INDEX

- A33 antibody, humanized, 688  
 A33 antigen, tumor-associated, 686  
 Abdominoperineal resection  
   in colorectal surgery, 505-506  
   local colorectal cancer recurrence following, 506  
   low anterior resection v, in colorectal cancer, 506-507  
 Ablation, radiofrequency, 520-521  
 Ablative therapy, for hepatic colorectal metastasis, 519-521  
 ABVD regimen, in primary pulmonary lymphoma, 312  
 ABVD-MOPP regimen, in primary pulmonary lymphoma, 312  
 Acquired immune deficiency syndrome, *see* AIDS  
 Acute lymphoblastic leukemia  
   adult, dose-intensive therapy for, 6-20  
   allogeneic stem-cell transplantation in, 7-8  
   Burkitt-type, 16  
   dose-intensive therapy for, 6-20  
   Ph positive, 15-16  
   progenitor cell transplant in, 2  
   progenitor-B, with T(4:11), 16-17  
   risk stratification in, 8-9  
 Acute myelocytic leukemia, progenitor cell transplant in, 2  
 Acute myeloid leukemia  
   allogeneic marrow transplantation in, 23  
   autologous marrow transplantation in, 23-25  
   incidence of, 21  
   marrow transplantation in, 21-34  
   refractory, 22-23  
 Adenoma  
   as cancer risk factor, 488-490  
   family history of, and screening, 493-494  
   history of, and screening, 493  
 Adenoviral vector, 465  
 Adenovirus, modified, in cancer, 465  
 Adenovirus expressing wild-type p 53, 463  
 Adjuvant therapy  
   clinical trials of, in colon cancer, 545-549  
   following liver resection, 519  
 African American men  
   early prostate cancer detection exam use by, 376-377  
   prostate cancer detection among, factors impacting on, 377-378  
   prostate cancer screening and, 375-381  
 AG2034, 613  
 AG331, 627-628  
 AG3340, 224  
 AG337, 627-628  
 AIDS  
   gastrointestinal lymphoma and, 332-333  
   NHL in, 249  
 Alcohol injection, for hepatic colorectal metastasis, 521  
 Allogeneic bone marrow transplantation  
   in acute myelogenous leukemia first remission, 25-29  
   autologous v, 29  
   high-dose cytarabine consolidation chemotherapy v, 26  
   in multiple myeloma, 79-80  
   non-high-dose cytarabine consolidation chemotherapy v, 26  
   in relapsed acute myeloid leukemia, 23  
 Allogeneic stem-cell transplantation  
   in acute lymphoblastic leukemia, 7-8  
   autologous v, 13-14  
   in chronic lymphocytic leukemia, 53-55  
   in chronic myelogenous leukemia, 63-64  
   clinical outcomes of, 53-54  
   from matched unrelated donors, 14-15, 64  
   from mismatched family members, 64  
   HLA-identical sibling donors for, 11, 63-64  
   late complications of, 94  
   leukemia-free survival following, 11  
   patient eligibility for, 53  
   published results of, 52  
   rationale for, 7-8  
   in relapsed acute lymphoblastic leukemia, 14  
   in second complete remission, 14  
   toxicity of, 55-56  
   trials of, v conventional chemotherapy trials, 11-12  
 Alpha 1-antichymotrypsin, 145  
 Alpha 2-macroglobulin, 145  
 Alpha-catenin, 462-464  
 ALVAC, 675  
 9-Aminocamptothecin  
   chemical structure of, 633  
   clinical activity of, 637-638  
   pharmacology of, 633  
 Amyloidosis  
   colchicine, melphalan, prednisone regimen in, 80-81  
   primary, 80-81  
   progenitor cell transplant in, 2  
 Anastomosis  
   coloanal, 509  
   contraindications to, 510-511  
   diversion issues and, 510  
   double-stapled, 509  
   J-pouch v straight, functional outcome of, 510  
 Androgen, in prostate cancer evolution, 415-416  
 Androgen blockade  
   clinical trial summary of, 166  
   combined, in prostate cancer, 166  
   favorable trials of, 166-167  
   meta-analysis of, 168  
   minimal, 168-169  
   total, 189  
   unfavorable trials of, 167-168  
 Androgen receptor(s)  
   functional domains of, 408  
   ligand-independent activation of, 409  
   mutations of, in prostate cancer, 413  
   in normal prostate development, 409-412  
   in prostate cancer, 386-387, 401-402, 407-421  
   in prostate epithelial cells, 409-410  
   in prostate stromal cells, 409-410  
   variations of, in prostate cancer, 412-415  
   working mechanism of, 408  
 Angiocentric cutaneous T-cell lymphoma, of childhood, 299  
 Angiogenesis  
   cyclooxygenase-2 and, 502  
   regulators of, 238-239

- Anti-B4 (CD19) immunotoxin, 89  
Anti-B4-blocked ricin, 89  
Antiandrogen, in prostate cancer, 164  
Antiandrogen withdrawal syndrome, 168  
Antibiotic therapy  
  in gastric MALT lymphoma, 326-328  
  outcome of, 327  
Antibody(ies)  
  Fv, 687  
  humanized, 688  
Antibody therapy  
  of colon cancer, 683-688  
  with unmodified mouse monoclonal antibody, 683-684  
Antibody-dependent cellular cytotoxicity, 195-196  
Antibody-directed enzyme prodrug therapy, 599-600  
Antibody-directed immunotoxin therapy, 687  
Antigen, colon cancer, 672-673  
Antigen ablation therapy, 370  
Antigen-presenting cell, in prostate cancer, 193, 197  
Antigen-specific vaccine, in prostate cancer, 197-198  
Antisense therapy, in prostate cancer, 464  
Antitumor immune priming, 193  
Antitumor immune response, 192-193  
Apoptosis  
  cell cycle and, 240-241  
  cyclooxygenase-2 and, 501  
  in prostate cancer therapy, 382-391  
Ashkenazi Jewish familial cancer, 479  
Aspartate transcarbamylase, 590  
Aspirin, drug-related cardiovascular side effects and, 163  
Autoimmune lymphocytic mastopathy, 358  
Autologous bone marrow transplantation  
  in acute myelogenous leukemia first remission, 29-30  
  allogeneic v, 29  
  in chronic myelogenous leukemia, 65-66  
  following acute myelogenous leukemia relapse, 23-25  
  representative studies of, 24  
Autologous stem-cell transplantation  
  in acute lymphoblastic leukemia, 12-13  
  allogeneic v, 13-14  
  in chronic lymphocytic leukemia, 50-53  
  late complications of, 94  
  in mediastinal large cell lymphoma, 255-256  
  leukemia-free survival following, 13  
  published results of, 52  
Autonomic nerve(s)  
  of pelvis, 508  
  preservation of, in rectal surgery, 508-509  
Azidothymidine, fluorouracil plus, 593  
B7-1, 677-678  
B-cell lymphoma, 302-303  
  cutaneous intravascular large, 302  
  diffuse large, 361  
  large, of leg, 301-302  
  marginal-zone, 301  
Bacille Calmette Guérin, in colon cancer, 551  
Bacillus Calmette-Guérin therapy, 442  
  in prostate cancer, 440  
BAGE family, 456-457  
BALT primary pulmonary lymphoma, 308-310  
Bannayan-Ruvalcaba-Riley syndrome, 479  
Barium enema, double-contrast, for colorectal cancer, 488  
Bcl-2, in prostate cancer, 384-386  
Benign prostatic hyperplasia, 411  
Bicalutamide  
  cost of, 170  
  in prostate cancer, 164-165  
Biliary glycoprotein, 673  
Biochemical progression, as response criterion, in prostate cancer, 176-177  
Bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisone regimen, in testicular lymphoma, 264  
Bleomycin, doxorubicin, cyclophosphamide, vindesine, prednisone regimen, in NHL, 89-90  
Bleomycin, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone regimen, in mediastinal large cell lymphoma, 254-255  
Bleomycin, mitoxantrone, cyclophosphamide, vindesine, prednisone regimen, in NHL, 89-90  
BMS-247616, 613-616, 641, 644  
BNPI-1350, 613  
BOF-A2  
  clinical activity of, 644  
  current status of, 641  
Bone marrow transplantation  
  in acute myeloid leukemia, 21-34  
  HLA-identical sibling, relapse following, 10  
  leukemia-free survival following, 9  
  published results of, 52  
  see also Allogeneic bone marrow transplantation; Autologous bone marrow transplantation  
Brachytherapy, in locally advanced prostate cancer, 205, 208-209  
Breast  
  lymphomas of, 357-363  
  normal, 357  
Breast cancer  
  autotransplant trends in, 36  
  high-dose autologous stem-cell-supported chemotherapy in, 35-47  
  metastatic, see Metastatic breast cancer  
  progenitor cell transplant in, 2  
Breast lymphoma  
  classification of, 359  
  definition of, 358  
  morphologic features of, 359-361  
  occurrence of, 358-359  
  presentation of, 358-359  
  primary, 360  
  secondary, 362-363  
  treatment of, 361-362  
Burkitt's lymphoma, 361, 92  
Burkitt-like lymphoma, 361  
BW1843U89, 626-627  
Bystander effect, 459-460  
C-CAM  
  altered expression of, 228  
  androgen regulation of, in prostate, 228

- C-CAM (*Continued*)  
  in cancer prevention, 232  
  expression of, in prostate cancer, 228-229  
  in malignant transformation, 230-231  
  in PC-3 growth suppression, 229-230  
  in prostate cancer, 227-233  
  in prostate cancer therapy, 231  
  studies of, 231-232  
  tissue distribution of, 228
- C-myc proto-oncogene, 387
- Calyculin A, 391
- Camptothecin  
  chemical structure of, 633  
  development of, 632  
  pharmacology of, 633
- Cancer care, attributable costs of, 562
- Cancer Rehabilitation Evaluation System Short Form, 692
- Cancer screening, for prostate cancer, and African American men, 375-381
- CAP-1, 676
- CAP1-6D, 676-677
- Capecitabine, 613, 614, 616-617  
  clinical activity of, 642-643  
  current status of, 641  
  oral, antitumor activity of, 617
- Carbohydrate antigen, 448-453  
  expression of, 449
- Carboplatin  
  high-dose, 100  
  in advanced prostate cancer, 187
- Carboplatin, etoposide, epirubicin regimen, in advanced prostate cancer, 188
- Carboplatin, etoposide regimen, in advanced prostate cancer, 188
- Carcinoembryonic antigen, 599-600, 672-673
- Carcinoembryonic antigen monitoring  
  clinical use of, 557  
  following large bowel cancer resection, 557-559  
  for metastatic disease response, 557
- Carcinoembryonic antigen screening, 556-560
- Carmustine, hepatic arterial, for colorectal metastasis, 525
- Carmustine, cyclophosphamide, etoposide regimen, in NHL, 90
- Carmustine, vincristine, melphalan, cyclophosphamide, prednisone regimen, in multiple myeloma, 76
- Caveolin-1, 425-426
- CB3717, 622-623  
  antitumor activity of, 623  
  chemical structure of, 623
- CC49 antigen, tumor-associated, 685-686
- CD30<sup>+</sup> large T-cell lymphoma, 295-297
- CD30<sup>-</sup> large T-cell lymphoma, 298
- CD28, 677
- CD4<sup>+</sup>, 675-676
- Cell, structure of, as prostate cancer therapy target, 234-236
- Cell-adhesion molecule, 227
- Cell-CAM105, 227
- Cell-cycle regulatory gene, 387-388
- Cell death regulation  
  in prostate cancer therapy, 382-391  
  therapeutic resistance and, 389-391
- Centroblast, 300
- Centrocyte, 300
- CGP 41251, 390
- 5,10-CH<sub>2</sub>H<sub>4</sub> folate, chemical structure of, 622
- Chemoprevention, of colorectal cancer, 499-504
- Chemoradiation, for sphincter preservation, 511
- Chemoradiotherapy, in rectal cancer, 541-543
- Chemoresistant relapse, 70
- Chemotherapy  
  adjuvant, clinical trials of, 545-549  
  in adult sarcoma, 120-122  
  in advanced prostate cancer, 428-438  
  allogeneic stem-cell transplantation v, 11-12  
  in CNS lymphoma, 348-354  
  combination, *see* Combination chemotherapy  
  cost of, 531-532  
  decreasing toxicity of, 530-531  
  dose-intensive, for adult malignancies, 1-5  
  FDG PET monitoring of, in colorectal cancer, 581  
  future directions in, 189-190  
  hepatic arterial, for colorectal metastasis, 524-535  
  high-dose, *see* High-dose chemotherapy  
  increasing response rate of, 529  
  intrahepatic v systemic, for hepatic metastases, 527  
  intraperitoneal, 536-539  
  liposome-encapsulated, 436  
  in locally advanced prostate cancer, 205  
  in mediastinal large cell lymphoma, 254-255  
  in multiple myeloma, 75-76  
  in primary non-Hodgkin's lymphoma, of bone, 271-274  
  in prostate cancer, 185-191  
  single-agent, 120-122, 187  
  in small cell carcinoma, 189  
  in testicular lymphoma, 263-265  
  toxicity of, 529-530, 550
- Chlorodihydroxypyrimidine, 614
- CHOP regimen, 88, 91  
  in mediastinal large cell lymphoma, 254-255  
  in primary pulmonary lymphoma, 312  
  in stage IV mycosis fungoides, 286  
  in testicular lymphoma, 264  
  in thyroid lymphoma, 320
- CHOP-B, in testicular lymphoma, 264
- Chronic lymphocytic leukemia  
  allogeneic stem-cell transplantation results in, 52  
  autografting in, clinical outcomes for, 51-53  
  autologous stem-cell transplantation results in, 52  
  bone marrow transplantation results in, 52  
  future directions in, 56-57  
  negative prognostic variables in, 49  
  potential phase III trial in, 57  
  progenitor cell transplant in, 2  
  stem-cell transplantation in, 48-61
- Chronic myelogenous leukemia  
  autologous bone marrow transplantation in, 65-66  
  current prognosis in, 63  
  phases of, 62-63

- Chronic myelogenous leukemia (*Continued*)  
 progenitor cell transplantation in, 2, 62-66  
 syngeneic transplantation in, 63
- Cimetidine, high-dose, plus activated lymphocytes, in prostate cancer, 195
- Cisplatin  
 fluorouracil plus, 597-598  
 hepatic arterial, for colorectal metastasis, 525  
 in sarcoma, 126  
 tumor resistance to, 107
- Cisplatin, dexamethasone, cytarabine regimen, in relapsed NHL, 88-89
- Citrus pectin, 240
- Classification  
 Kiel, 308  
 of lymphomas, 316-317  
 of mycosis fungoides, 278  
 REAL, 308, 316  
 TNMB, 278
- CNS lymphoma  
 characterization of, 346-347  
 cyclophosphamide in, 351-352  
 cytarabine in, 352-353  
 management of, 347-350  
 methotrexate in, 350-351  
 presentation of, 347  
 thiotepa in, 353  
 vincristine in, 353-354
- Coactivator, 408-409
- Codon 12 mutation, 675
- Colchicine, melphalan, prednisone regimens, in amyloidosis, 80-81
- Colon cancer  
 adjuvant chemotherapy in, 545-549  
 adjuvant radiation in, 551  
 antibody therapy of, 683-688  
 Bacille Calmette Guérin in, 551  
 fluorouracil portal vein infusion in, 550-551  
 fluorouracil, leucovorin regimen in, 546-547  
 monoclonal antibody therapy in, 551  
 recombinant vaccines for, 672-679  
 stage II, 549-550  
 staging of, 546
- Colon J-pouch reservoir, 509-510
- Colonoscopy, for colorectal cancer, 487-488
- Colorectal cancer  
 altered C-CAM expression in, 228  
 attributable costs of, 564-565  
 average-risk guidelines for, 492-495  
 average-risk patients for, 485-488  
 chemoprevention of, 499-504  
 comparative health economic analyses of, 565-567  
 cross-sectional imaging of, 569-576  
 CT in, 569-572  
 factors associated with, 490  
 family history of, 490  
 first-line chemotherapy in, results of, 601  
 future directions in, 587-588  
 genetic alterations associated with, 489  
 helical CT in, 570-571  
 hepatic metastasis of, surgical therapy for, 514-523
- Colorectal cancer (*Continued*)  
 hereditary, 478-484  
 high-risk patients for, 488-492  
 history of, 490-491  
 imaging in, 575  
 incidence of, 486  
 inherited susceptibility to, genetic testing for, 566  
 interferon in, 669-670  
 intraperitoneal chemotherapy in, 536-539  
 laparoscopic v open resection surgery in, 505  
 lateral margins in, 507  
 local excision in, 505-506  
 mean costs of, 565  
 metastatic, 572-573  
 MRI in, 572-573  
 new anticancer agents for, in France, 659  
 new drugs in, 613  
 overview of, 475-477  
 personal history of, and screening, 494  
 PET in, 577-583  
 pharmacological prevention of, 502-503  
 quality of life assessment in, 691-695  
 quality of life-based clinical studies in, 693-694  
 recurrent, FDG PET detection of, 578-579  
 risk factors for, 488, 489  
 screening cost-effectiveness in, 495  
 screening for, 485-498  
 staging of, FDG PET for, 578  
 surveillance guidelines for, 492-493
- Colorectal cancer subscale, 693
- Combination chemotherapy  
 in diffuse aggressive NHL, 87-88  
 for hepatic colorectal metastasis, 529  
 high-dose, 126-127  
 in prostate cancer, 187-189  
 in sarcoma, 3
- Combined modality therapy  
 in gastric lymphoma, 331  
 in primary NHL, of bone, 271-274
- Comparative genomic hybridization analysis, 402-403
- Comparative health economic studies, definition of, 562
- Computed tomography  
 in colorectal cancer, 569-572  
 helical, in colorectal cancer, 570-571  
 in hepatic colorectal metastasis, 518  
 for liver resection evaluation, 517-519
- Computed tomography colography, 571-572
- Connexin protein, 460
- Corepressor, 408-409
- Cost(s)  
 analysis methodology for, 561-564  
 assessing, 563  
 attributable, 562  
 of chemotherapy, 566-567  
 of colorectal cancer therapy, 561-568  
 comparative, definition of, 562  
 of follow-up, following potentially curative therapy, 567  
 of hepatic arterial chemotherapy, 531-532  
 relevant, defining, 563
- Cost minimization study, definition of, 562
- Cost-benefit analysis, definition of, 562

- Cost-effectiveness  
  analysis of, methodology for, 561-564  
  of colorectal cancer screening, 495  
  of colorectal cancer therapy, 561-568  
  definition of, 562  
  ratios of, 562  
Cost-effectiveness threshold, 562-563  
Cost-utility analysis, definition of, 562  
Cowden syndrome, 479  
CPT-11  
  clinical activity of, 634-636  
  see also Irinotecan  
Creatine kinase-BB isoenzyme, 145  
Crosti's lymphoma, 300  
Cryoablation, for hepatic colorectal metastasis, 520  
Cryotherapy, in locally advanced prostate cancer, 205, 209-210, 212  
CT, see Computed tomography  
CTLA-4, 677  
Cutaneous B-cell lymphoma, primary, 299-300  
Cutaneous delayed-type hypersensitivity, 442, 445, 458  
Cutaneous Hodgkin's disease, primary, 299  
Cutaneous lymphoid hyperplasia, 301  
Cutaneous lymphoma  
  classification of, 290-291  
  diagnosis of, 292-294  
  pathogenesis of, 291-292  
  staging, 294  
Cutaneous plasmacytoma, 302  
Cutaneous T-cell lymphoma  
  classification of, 295  
  diagnosis of, 294-295  
  non-mycosis fungoides, 297  
  pleomorphic small-medium-sized, 297-298  
Cyclic adenosine monophosphate, 391  
Cyclin-dependent kinase, 599-600  
Cyclooxygenase, in colorectal cancer prevention, 502-503  
Cyclooxygenase-1, cyclooxygenase-2 v, 500  
Cyclooxygenase-2  
  carcinogenesis and, 501-502  
  contribution of, to tumorigenesis, 500-501  
  inhibition of, 499-504  
Cyclophosphamide  
  in adjuvant high-dose therapy, 44  
  in CNS lymphoma, 348, 351-352  
  in Ewing tumor, 128  
  high-dose, in prostate cancer, 430-431  
  immunogenicity and, 442  
  in mediastinal large cell lymphoma, 254-255  
  oral, in prostate cancer, 430-431  
  in sarcoma, 126  
  in testicular lymphoma, 264  
Cyclophosphamide, carmustine, etoposide regimen, in NHL, 90  
Cyclophosphamide, doxorubicin regimen, in advanced prostate cancer, 188  
Cyclophosphamide, doxorubicin, vincristine, prednisone, bleomycin regimen, in testicular lymphoma, 264  
Cyclophosphamide, doxorubicin, vindesine, bleomycin, prednisone regimen, in NHL, 89-90  
Cyclophosphamide, etoposide regimen, in advanced prostate cancer, 188  
Cyclophosphamide, tumor-infiltrating lymphocyte regimen, in prostate cancer, 195  
Cyclophosphamide, mitoxantrone, vindesine, bleomycin, prednisone regimen, in NHL, 89-90  
Cyclophosphamide, vincristine, carmustine, melphalan, prednisone regimen, in multiple myeloma, 76  
Cyclophosphamide, vincristine, doxorubicin, methylprednisolone, in myeloma, 77-78  
Cyclophosphamide, vincristine, prednisone regimen, in pulmonary lymphoma, 312  
Cyproterone acetate  
  in prostate cancer, 162  
  side effects of, 164  
  studies of, 165-166  
Cystectomy, radical, with pelvic extirpation, in locally advanced prostate cancer, 205-206  
Cytarabine, in CNS lymphoma, 352-353  
Cytarabine, dexamethasone, cisplatin regimen, in relapsed NHL, 88-89  
Cytokine(s), 101  
  as biologic adjuvant, 679  
Cytokines, 101  
Cytosine arabinoside, in CNS lymphoma, 348  
Cytosine deaminase, 600  
Cytoskeleton, as prostate cancer therapy target, 235-236  
  
Dacarbazine, in sarcoma, 120-122, 124  
Dactinomycin, in sarcoma, 128  
Delayed-type hypersensitivity, 458  
  cutaneous, 442, 445  
Deoxyuridine triphosphate, 589-590  
DETOX, mutant ras peptide regimen, in prostate cancer, 195  
Dexamethasone, cisplatin, cytarabine regimen, in relapsed NHL, 88-89  
Dexamethasone, vincristine, doxorubicin regimen, in autologous transplantation, 76-77  
DHAP regimen, 90-91  
Dichloromethotrexate, hepatic arterial, for colorectal metastasis, 525  
Diethylstilbestrol, 207  
  cost of, 170  
  in prostate cancer, 163  
  studies of, in prostate cancer, 165  
Differential display-polymerase chain reaction, 422-427  
Differentiation therapy, in prostate cancer, 371  
Digital rectal examination  
  positive predictive value of, 141  
  in prostate cancer detection, 141  
  in prostate cancer screening, 375-376  
Dihydrofolate, 590  
Dihydrofolate reductase, 590, 613  
Dihydropyrimidine dehydrogenase, 607, 613-614  
Dihydrotestosterone, in prostate cancer, 162  
Diphtheria toxin interleukin-2 fusion protein, in mycosis fungoides, 287  
Dipyridamole, 590  
  fluorouracil plus, 593-594  
Discrete colonic adenoma and colorectal cancer, 479  
Docetaxel, estramustine regimen, in prostate cancer, 434  
Dose-intensive therapy, for adult acute lymphoblastic leukemia, 6-20



- Doxorubicin, 390  
 in adjuvant high-dose therapy, 44  
 in combination chemotherapy, 123, 124  
 hepatic arterial, for colorectal metastasis, 525  
 in mediastinal large cell lymphoma, 254-255  
 in myeloma, 77-78  
 in prostate cancer, 430-431  
 in sarcoma, 120-122  
 in testicular lymphoma, 264
- Doxorubicin, cyclophosphamide regimen, in advanced prostate cancer, 188
- Doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in testicular lymphoma, 264
- Doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone regimen, in NHL, 89-90
- Doxorubicin, estramustine, vinblastine, ketoconazole regimen, in advanced prostate cancer, 188
- Doxorubicin, fluorouracil, mitomycin regimen, in advanced prostate cancer, 188
- Doxorubicin, methotrexate, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in mediastinal large cell lymphoma, 254-255
- Doxorubicin, vincristine, dexamethasone regimen, in autologous transplantation, 76-77
- Doxorubicin, vincristine, methylprednisolone, cyclophosphamide, in myeloma, 77-78
- E-cadherin, 462-464
- Efficacy, assessing, 563
- Electron-beam therapy  
 in mycosis fungoides, 281-283  
 in stage IB-IIA mycosis fungoides, 283-284  
 in stage IIB mycosis fungoides, 284-285  
 in stage III mycosis fungoides, 285-286  
 in stage IV mycosis fungoides, 286
- Emiterfur  
 clinical activity of, 644  
 current status of, 641
- Endothelin-1, 399
- Enema, double-contrast barium, for colorectal cancer, 488
- Eniluracil, oral fluorouracil regimen  
 clinical activity of, 641-642  
 current status of, 641
- Epidermal growth factor, 400, 409, 410, 599-600
- Epirubicin, carboplatin, etoposide regimen  
 in advanced prostate cancer, 188  
 in sarcoma, 120-122, 124
- Epitope, cytotoxic T-lymphocyte, 672-673, 676-677
- Estramustine  
 clinical trials of, 432  
 in prostate cancer, 431-434
- Estramustine, docetaxel regimen, in prostate cancer, 434
- Estramustine, etoposide regimen  
 in advanced prostate cancer, 188  
 in prostate cancer, 433
- Estramustine, etoposide, paclitaxel regimen, in prostate cancer, 434
- Estramustine, paclitaxel regimen, in prostate cancer, 433-434
- Estramustine, vinblastine, ketoconazole, doxorubicin regimen, in advanced prostate cancer, 188
- Estramustine, vinblastine regimen, in prostate cancer, 432-433
- Estramustine, vinorelbine, etoposide regimen, in advanced prostate cancer, 188
- Estramustine, vinorelbine regimen, in prostate cancer, 433
- Estrogen therapy, in prostate cancer, 164
- Ethanol injection, for hepatic colorectal metastasis, 521
- Ethynyluracil, 613, 617
- Etoposide  
 in advanced prostate cancer, 187  
 in sarcoma, 126
- Etoposide, cyclophosphamide, carmustine regimen, in NHL, 90
- Etoposide, cyclophosphamide regimen, in advanced prostate cancer, 188
- Etoposide, epirubicin, carboplatin regimen, in advanced prostate cancer, 188
- Etoposide, estramustine regimen  
 in advanced prostate cancer, 188  
 in prostate cancer, 433
- Etoposide, estramustine, paclitaxel regimen, in prostate cancer, 434
- Etoposide, estramustine, vinorelbine regimen, in advanced prostate cancer, 188
- Etoposide, infusional carboplatin regimen, in advanced prostate cancer, 188
- European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-C30, 692, 694
- Ewing tumor, 127-130
- External-beam radiation therapy  
 dose-response of, 152-154  
 hormonal therapy plus, in prostate cancer, 208  
 in locally advanced prostate cancer, 205, 206-207  
 in prostate cancer treatment, 151
- Extranodal lymphoma, 249-250
- <sup>18</sup>F-2-Fluoro-2-deoxyglucose  
 biochemistry of, 577-578  
 uptake of, 578
- F-MACHOP regimen, 90-91
- F19, 687
- FACT-C, 693
- FACT-colorectal quality of life instrument, 693
- FACT-G, 693
- Familial adenomatous polyposis, 478-479, 491
- Familial colorectal cancer, 480-481  
 genes of, 479
- Familial juvenile polyposis syndrome, 479, 491-492
- Family history  
 of adenoma, 490  
 of colorectal adenoma, 493-494  
 of colorectal cancer, 490  
 screening for, 493-494
- Fas, 390
- FDG PET  
 in colorectal cancer, for staging, 578  
 for colorectal cancer therapy monitoring, 581  
 in hepatic colorectal metastasis, 518-519  
 for intraperitoneal colorectal cancer, 580-581  
 for recurrent liver metastatic cancer, 580  
 for recurrent pelvic colorectal cancer, 579-580



- FDG PET (*Continued*)  
  for rising carcinoembryonic antigen, 579, 580  
  in recurrent colorectal cancer detection, 578-579
- Fecal occult blood test, for colorectal cancer, 486
- Fibroblast activation protein, 687-688
- Fibroblast growth factor-7, 410
- Flare phenomenon, 178  
  in prostate cancer hormonal therapy, 164
- Flavones, in prostate cancer, 222-223
- Flavopiridol, 240-241  
  in prostate cancer, 223  
  structure of, 222
- Fluorodeoxyuridine  
  hepatic arterial, for colorectal metastasis, 525  
  responses to, via internal pump, 525
- Fluorodeoxyuridine monophosphate, 589-590
- Fluorodeoxyuridine triphosphate, 589-590
- Fluoropyrimidine  
  activation of, metabolic pathway of, 590  
  antitumoral activity of, determinants of, 591  
  mechanism of action of, 606-607  
  metabolism of, 606-607  
  oral, 640-646
- Fluoropyrimidine antimetabolite, chemical structures of, 614
- Fluoropyrimidine resistance  
  mechanisms of, 608  
  thymidylate synthase for, 607-608
- Fluorouracil, 614  
  adjuvant, 548  
  antitumor activity of, 615, 616, 617  
  azidothymidine plus, 593  
  biochemical modulation of, 590-591  
  chemical structure of, 622  
  chronomodulation of, 597  
  cisplatin plus, 597-598  
  in colon cancer, 546-547  
  in colorectal cancer, history of, 587, 588  
  continuous infusion *v* bolus, clinical trials of, 595  
  continuous intravenous infusion *v* bolus, 552  
  dipyridamole plus, 593-594  
  dosing of, 548  
  enhancing cytotoxicity of, 599-600  
  folinic acid plus, 591-592  
  hepatic arterial, for colorectal metastasis, 525  
  interferon biomodulators of, 663-670  
  interferon plus, 593  
  intracellular activation of, 607  
  intraperitoneal, in colorectal cancer, 536-538  
  irinotecan plus, 598-599  
  levamisole plus, 594  
  mechanism of, 589-590  
  metabolic modulation of, 615  
  metabolism of, 589-590  
  methotrexate plus, 592  
  mitomycin plus, 597  
  modulators of, clinical efficacy of, 591  
  oral derivatives of, 597  
  oxaliplatin synergy with, 647-648  
  PALA plus, 594  
  pharmacodynamics of, 589-591  
  pharmacokinetics of, 589-591
- Fluorouracil, 614 (*Continued*)  
  portal vein infusion of, 550-551  
  as radiosensitizer, 599  
  raltitrexed plus, 599  
  response to, tumor-associated predictive factor for, 600-601  
  scheduling of, 594-597  
  thymidylate synthase inhibitor development following, 621-628  
  toxicity of, 550, 596  
  trimethexate plus, 593  
  24-hour, plus folinic acid, 596  
  zidovudine plus, 593
- Fluorouracil prodrug  
  mechanism-based selective metabolism of, 614-617  
  therapeutic selectivity model of, 618
- Fluorouracil resistance, cell-cycle gene alteration for, 609-610
- Fluorouracil, folinic acid, oxaliplatin regimen, in colorectal cancer, 598
- Fluorouracil, interferon regimen, preclinical studies of, 663-664
- Fluorouracil, interferon-alpha regimen  
  clinical trials of, 665-666, 667  
  pharmacokinetics of, 664-665  
  phase II trials of, 665  
  phase III trials of, 667
- Fluorouracil, interferon-alpha, folinic acid regimen, 668  
  clinical trials of, 666-667
- Fluorouracil, interferon-beta regimen, clinical trials of, 668-669
- Fluorouracil, mitomycin, doxorubicin regimen, in advanced prostate cancer, 188
- Fluorouracil, oxaliplatin regimen, in colorectal cancer, 651-657
- Fluorouracil, oxaliplatin, folinic acid regimen  
  in colorectal cancer, 651-657  
  main grade 3-4 WHO toxicities of, 653  
  in metastatic colorectal cancer, 655  
  phase II trials of, 654-655  
  phase III trials of, 655-657  
  second-line antitumoral activity of, 652  
  in untreated advanced colorectal cancer, 654-655
- Fluorouridine triphosphate, 589-590
- Fluoroxylglucose PET, *see* FDG-PET
- Flutamide  
  adjuvant, 548  
  in colon cancer, 546-547  
  cost of, 170  
  dosing of, 548  
  leuprolide with, overall survival following, 167  
  in prostate cancer, 164  
  studies of, 165  
  toxicity of, 550
- FOLFOX regimens, 652
- Folinic acid, 613  
  fluorouracil plus, 591-592  
  24-hour fluorouracil plus, 596  
  UFT plus, 616
- Folinic acid, fluorouracil, oxaliplatin regimen, in colorectal cancer, 598
- Folinic acid, interferon-alpha, fluorouracil regimen, 668  
  clinical trials of, 666-667
- Folinic acid, oxaliplatin, fluorouracil regimen  
  in colorectal cancer, 651-657  
  main grade 3-4 WHO toxicities of, 653

- Folinic acid, oxaliplatin, fluorouracil regimen (*Continued*)  
  in metastatic colorectal cancer, 655  
  phase II trials of, 654-655  
  phase III trials of, 655-657  
  second-line antitumoral activity of, 652  
  in untreated advanced colorectal cancer, 654-655
- Follicle-center cell lymphoma, 300-301, 361
- Folypolyglutamyl synthase, 590
- FT, antitumor activity of, 615
- Ftorafur, 614
- Functional Assessment of Cancer Therapy-General, 692
- Functional Living Index-Cancer, 692
- Fusion protein, in mycosis fungoides, 286-287
- Fv antibody, 687
- Gadolinium, 573
- Gadopentate dimeglumine, 573
- GAGE family, 456-457
- Gap junction intercellular communication, 460
- Gardner's syndrome, 491
- Gastric lymphoma  
  limited-stage, therapy outcome in, 330  
  primary, optimal therapy in, 329-332
- Gastric MALT lymphoma, antibiotic therapy in, 326-328
- Gastrointestinal lymphoma  
  clinical features of, 325  
  distribution of, 325  
  following solid-organ transplantation, 333  
  immunodeficiency and, 332-333  
  incidence of, 324  
  optimal therapy in, 329-332  
  presentation of, 325-326  
  staging of, 325-326
- Gastrointestinal tract  
  mantle-cell lymphoma of, 328-329  
  NHL of, 324-337
- Gemcitabine, in advanced prostate cancer, 187
- Gene therapy  
  ex vivo, 455  
  in prostate cancer, 455-466  
  radical prostatectomy and, 213  
  suicide, 459-462
- Gene-directed enzyme prodrug therapy, 459-462
- Germ cell tumor(s)  
  high-dose autologous stem-cell-supported chemotherapy for, 106-118  
  incidence of, 106
- Gleason score, 369  
  in clinically localized prostate cancer, 203  
  pretreatment PSA and, 156
- Globo H, 449
- Globo H antigen, 451
- Glycinamide ribonucleotide formyltransferase, 613
- Glycoprotein antigen, 448-453  
  expression of, 449
- GM-CSF, 442-443
- Goserelin acetate, cost of, in prostate cancer, 170
- Graft-versus-host disease, 54
- Graft-versus-leukemia effect, 8, 54-55, 94
- Graft-versus-lymphoma effect, 94
- Granulocyte-macrophage colony-stimulating factor, 442-443, 679
- Growth factor, 400  
  GM-CSF, 442-443
- HAMA, 684
- Hamartomatous polyposis, 479-480
- Head and neck lymphoma(s)  
  diagnosis of, 339  
  histologic classification in, 339  
  presenting symptoms of, 338  
  sites of, 338  
  staging in, 339  
  treatment of, 344
- Health profile, 692
- Helicobacter pylori*, 249, 326-328
- Hepatic arterial chemotherapy  
  cost of, 531-532  
  decreasing extrahepatic disease in, 531  
  for colorectal metastasis, 524-535  
  multidrug, 529  
  quality of life and, 531  
  toxicity of, 529-530
- Hepatic artery catheter implant  
  constant flow, 526  
  with fluorodeoxyuridine, for colorectal metastasis, 525-527  
  insertion of, 526-527
- Hepatic colorectal metastasis  
  ablative therapies for, 519-521  
  combination chemotherapy for, 529  
  CT portogram in, 518  
  hepatic arterial chemotherapy for, 524-535  
  intrahepatic v systemic chemotherapy for, 527  
  surgical therapy of, 514-523  
  treatment options for, 515
- Hepatic infusional therapy, studies of, 527-528
- Hepatic resection, *see* Liver resection
- Hepatoma, altered C-CAM expression in, 228
- HER-2-*neu*, 672-673
- Hereditary colon cancer  
  classification of, 478  
  diagnosing, 481  
  family information session in, 482  
  managing, 481  
  molecular screening for, 481-482  
  syndromes of, 479, 491-492
- Hereditary colorectal cancer syndromes, screening in, 494-495
- Hereditary mixed polyposis syndrome, 479
- Hereditary nonpolyposis colorectal cancer, 480, 492  
  genes of, 479  
  management of, 482-483  
  surveillance in, 482-483
- Herpes simplex virus thymidine kinase, 459-460
- High-dose autologous stem-cell-supported chemotherapy  
  adjuvant, 41-45  
  in adult sarcomas, 119-130  
  in breast cancer, 35-47  
  conventional approaches to, 36  
  in early-stage disease, 41-45  
  end points in, 37  
  as first-line therapy, 112-114

- High-dose autologous stem-cell-supported chemotherapy  
(Continued)  
for germ cell tumors, 106-118  
in metastatic disease, 37-39  
phase I-II trials of, 39  
for primary extragonadal germ cell tumors, 114  
randomized trials of, 41  
rationale for, 35  
regimen design for, 37  
as salvage therapy, 107-112  
timing of, 39-41
- High-dose chemotherapy  
in multiple myeloma, 74-83  
in ovarian cancer, 99-105  
in primary amyloidosis, 74-83  
in sarcoma, 126  
standard salvage therapy v, 103  
stem-cell transplantation and, 101-103  
transplantation-supported, in NHL, 84-98
- High-dose cytarabine consolidation chemotherapy  
allogeneic bone marrow transplantation v, 26  
non-, v allogeneic bone marrow transplantation, 26
- HIV infection, gastrointestinal lymphoma and, 332-333
- Hodgkin's disease, 312  
allografting in, 69-70  
complete remission in, relapse following, 69  
new directions in, 71-72  
primary cutaneous, 299  
primary refractory, 68-69  
progenitor cell transplant in, 2  
recommendations in, 70-71  
standard salvage therapy in, 67-68  
transplantation and, 67-73
- Hormonal therapy  
in advanced prostate cancer, 162-173  
in locally advanced prostate cancer, 205  
radiation plus, 207-208  
surgery plus, 210-212
- Hormone therapy, in prostate cancer, 415-416
- Hormone-response element, 386
- Hospital Anxiety and Depression Scale, 692, 694
- Human antimouse antibody, 684
- Human prostate-specific kallikrein 2 promoter, 465-466
- Humanized A33 antibody, 688
- Hydroa vacciniforme*, 299
- Hydroxyurea, 590
- Ifosfamide  
in combination chemotherapy, 123  
high-dose, 122  
in sarcoma, 120-122
- IL-2, 679
- Immune response, antitumor, 192-193
- Immune system, in prostate cancer, 456
- Immization  
diversified prime and boost, 675  
with Oncovax-P, 442-445
- Immunotherapy, for hepatic colorectal metastasis, 528
- Immunoglobulin molecule, modifying, 687
- Immunosuppression, cyclooxygenase and, 501
- Immunotherapy  
with intraprostatic leukocyte interleukin, 439-441  
in prostate cancer, 370
- Immunotoxin, anti-B4 (CD19), 89
- Immunotoxin therapy, antibody-directed, 687
- Indocin, liposomal ImmTher regimen, in prostate cancer, 195
- Inflammation, cyclooxygenase and, 501
- Inflammatory bowel disease  
history of, 490  
screening for, 494
- Insulin-like growth factor, 409, 410
- Intensity-modulated radiotherapy  
dose distribution for, 158  
in prostate cancer, 152-153
- Intercellular adhesion molecule-1, 677
- Interferon, 590  
in colorectal cancer, 669-670  
as fluorouracil biomodulators, 663-670  
fluorouracil plus, 593  
plus radiolabeled monoclonal antibodies, in prostate cancer, 195
- Interferon, fluorouracil regimen, preclinical studies of, 663-664
- Interferon-alpha  
effects of, on fluorouracil pharmacokinetics, 664  
enzyme activity following, 669
- Interferon-alpha, fluorouracil regimen  
clinical trials of, 665-666, 667  
pharmacokinetics of, 664-665  
phase II trials of, 665  
phase III trials of, 667
- Interferon-alpha, fluorouracil, folinic acid regimen  
clinical trials of, 666-667, 668, 668
- Interferon alfa-2a, in colon cancer, 547-548
- Interferon-beta, enzyme activity following, 669
- Interferon-beta, fluorouracil regimen, clinical trials of, 668-669
- Interferon-gamma  
in breast cancer, (s)32-33  
in prostate cancer, 456
- Interleukin-1 beta, 439-440
- Interleukin-2, 443  
polyethylene glycol regimen, in prostate cancer, 195  
tumor-infiltrating lymphocyte regimen, in prostate cancer, 195
- Interleukin-2 diphtheria toxin fusion protein, in mycosis fungoides, 287
- Interleukin-6, 400
- International Index, in primary pulmonary lymphoma, 312
- International Prognostic Index, 90
- Intestinal lymphoma, therapy for, 331-332
- Intraperitoneal chemotherapy  
adjuvant, 538  
clinical trials of, 537-538  
in colorectal cancer, 536-539  
limitations of, 536  
multiagent hyperthermic, 538  
practical considerations with, 537  
theoretical concerns with, 537
- Invasiveness, cyclooxygenase and, 501-502

- Irinotecan, 613  
     chemical structure of, 633  
     clinical activity of, 634-636  
     in colon cancer, 552  
     fluorouracil plus, 598-599  
     oxaliplatin plus, 657-658  
     pharmacology of, 633  
     phase II trials of, 634, 636
- Janus face of androgen action, 410-412
- JM216, 613
- Keratinocyte growth factor, 409, 410
- Ketoconazole, doxorubicin, estramustine, vinblastine regimen,  
     in advanced prostate cancer, 188
- Keyhole limpet hemocyanin, 442-443, 448
- Kiel classification, 308
- Lactic dehydrogenase, 254
- Large B-cell lymphoma, primary mediastinal, 251-258
- LDQ10, 450
- League table, 562
- Lemetrexol, 613
- Leucovorin, 613  
     adjuvant, 548  
     in colon cancer, 546-547  
     dosing of, 548  
     fluorouracil plus, 591-592  
     toxicity of, 550  
     24-hour fluorouracil plus, 596
- Leukemia, acute, as transplantation complication, 93
- Leukocyte interleukin  
     clinical trial of, 441  
     intraprostatic, 439-441  
     rationale for, 439-440
- Leuprolide, flutamide with, 167
- Leuprolide acetate, cost of, 170
- Levamisole  
     adjuvant, 548  
     in colon cancer, 546-547  
     dosing of, 548  
     fluorouracil plus, 594  
     toxicity of, 550
- Lewis-Y antigen, in colon cancer therapy, 687
- Liarozole, 237
- Limonene, 218-220
- Liposomal ImmTher, indocin regimen, in prostate cancer, 195
- Liposome, 442
- Liposome-encapsulated drug, 195  
     in prostate cancer, 436
- Liver resection  
     adjuvant therapy following, 519  
     complications of, 515  
     in metastatic colorectal cancer, 514-515  
     in patients over 70, 516  
     patient selection criteria for, 515-517  
     recurrence risk score for, and survival, 517  
     results of, in metastatic colorectal cancer, 515
- Loss of heterozygosity, 388, 462-464
- Low anterior resection  
     abdominoperineal v, in colorectal cancer, 506-507  
     local colorectal cancer recurrence following, 506
- Luteinizing hormone-releasing hormone, 210-212
- Luteinizing hormone-releasing hormone agonists  
     in prostate cancer, 163  
     studies of, 165
- LY231514, 625-626  
     chemical structure of, 625
- LY309887, 613
- Lymphoblastic lymphoma, 92
- Lymphocyte, activated, plus high-dose cimetidine, in prostate  
     cancer, 195
- Lymphocyte function-associated antigen-3, 677
- Lymphocytic interstitial pneumonia, 309-310
- Lymphoma  
     diffuse large B-cell, of mediastinum, 93  
     high-grade, Burkitt-like B-cell, 92-93  
     low-grade, natural history of, 85
- Lymphoma(s)  
     of breast, 357-363  
     classification of, 316-317  
     extranodal, 249-250  
     follicle-center, 361  
     gastrointestinal, 324-337  
     of head and neck, 338-345  
     low-grade, of MALT type, 308, 309  
     MALT, 320  
     of nasal cavity, 342-343  
     of paranasal sinus, 343-344  
     of salivary gland, 341-342  
     testicular, *see* Testicular lymphoma
- Lymphomatoid granulomatosis, 309, 312
- M-BACOD regimen, 88
- MACOP regimen, in CNS lymphoma, 349
- MACOP-B regimen, 88, 90-91  
     in CNS lymphoma, 349  
     in mediastinal large cell lymphoma, 254-255
- Macroaggregated albumin scan, technetium, 526
- MAGE family, 456-457
- Magnetic resonance cholangiography, 573
- Magnetic resonance cholangiopancreatography, 573
- Magnetic resonance imaging  
     basic principles of, 572  
     in colorectal cancer, 572-573  
     contrast agents for, 573-574  
     of hepatic metastases, 574-575  
     for liver resection evaluation, 517-519  
     in primary NHL, of bone, 271
- MALT lymphoma, 320
- MALToma, 311-312
- Mantle cell lymphoma, 91-92  
     of gastrointestinal tract, 328-329
- Marginal-zone B-cell lymphoma, 301
- Matrix metalloproteinases, 239-240
- McGill Pain Questionnaire, 692, 694
- MDAM, 613
- MDRI, 390
- MDX-H210, 196

- Mechlorethamine hydrochloride  
 in mycosis fungoides, 281-283  
 in stage IB-IIA mycosis fungoides, 283-284  
 in stage IIB mycosis fungoides, 284-285  
 in stage III mycosis fungoides, 285-286  
 in stage IV mycosis fungoides, 286
- Mediastinal large cell lymphoma  
 autologous stem-cell transplantation in, 255-256  
 CHOP regimen in, 254-255  
 clinical picture of, 253-254  
 diagnosis of, 252-253  
 genotype of, 252  
 histopathology of, 251-252  
 immunophenotype of, 252  
 MACOP-B regimen in, 254-255  
 pathogenesis of, 253  
 prognostic factors in, 255  
 relapse in, 255-256  
 response evaluation in, 255  
 treatment of, 254-255
- Mediastinum  
 diffuse large B-cell lymphoma of, 93  
 primary large cell lymphoma of, 251-258
- Medical Outcome Study Short Form Health Survey, 692-694
- Medroxyprogesterone acetate, studies of, in prostate cancer, 165
- Melphalan  
 in multiple myeloma, 77  
 in sarcoma, 126
- Melphalan, colchicine, prednisone regimen, in amyloidosis, 80-81
- Melphalan, prednisone regimen, in multiple myeloma, 75
- Melphalan, vincristine, carmustine, cyclophosphamide, prednisone regimen, in multiple myeloma, 76
- Mesorectal excision, in colorectal cancer, 507-508
- Metastasis-related gene, 423-425
- Metastatic cascade, 239-240
- Methotrexate, 590, 613  
 fluorouracil plus, 592  
 in CNS lymphoma, 348, 350-351
- Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in mediastinal large cell lymphoma, 254-255
- Methylprednisolone, in myeloma, 77-78
- Methylprednisolone, vincristine, doxorubicin, cyclophosphamide, in myeloma, 77-78
- MFE-23, 687
- Microsatellite-marker analysis, 482
- Mifepristone, 409
- Minimal residual disease, detecting, 50-51
- Minitransplant, 55
- Mitomycin  
 in advanced prostate cancer, 187  
 fluorouracil plus, 597  
 hepatic arterial, for colorectal metastasis, 525
- Mitomycin, doxorubicin, fluorouracil regimen, in advanced prostate cancer, 188
- Mitoxantrone, in hormone-resistant prostate cancer, 434-435
- Mitoxantrone, cyclophosphamide, vindesine, bleomycin, prednisone regimen, in NHL, 89-90
- MMACI-PTEN, 388-389
- Monoclonal antibody(ies)  
 in mycosis fungoides, 286  
 radiolabeled, plus interferon, in prostate cancer, 195
- Monoclonal antibody therapy, in colon cancer, 551
- Monoterpenes, in prostate cancer drug development, 218-220
- MOPP regimen, in primary pulmonary lymphoma, 312
- MOPP-ABVD regimen, in primary pulmonary lymphoma, 312
- Mouse prostate reconstitution model system, 388
- MRI, *see* Magnetic resonance imaging
- mu Ab 17-1A, 684
- MUC-1, 448, 449-453, 672-673
- MUC-2, 450-453
- Mucin  
 cancer v normal, 450  
 in cancer therapy, 457
- Mucosa-associated lymphoid tissue-derived lymphoma, 249
- Multidimensional Fatigue Inventory, 692, 694
- Multidrug resistance, cell death regulation and, 389-391
- Multiple lymphomatous polyposis, 328-329
- Multiple myeloma  
 allogeneic bone marrow transplantation in, 79-80  
 autologous transplantation in, 76-79  
 characterization of, 74  
 chemotherapy in, 75-76  
 diagnosis of, 74-75  
 initial therapy in, 75  
 melphalan in, 77  
 radiotherapy in, 75  
 syngeneic transplantation in, 79  
 total body irradiation in, 77-78  
 treatment of, 75
- Mutant ras peptide, DETOX regimen, in prostate cancer, 195
- Mycosis fungoides  
 characterization of, 276  
 classification of, 278  
 clinical features of, 277  
 clinical staging system in, 279  
 diagnosis of, 277-278  
 emerging novel therapies for, 286-287  
 etiology of, 276-277  
 management of, 280-281  
 prognosis in, 278-280  
 stage IA, 281-283  
 stage IB-IIA, 283-284  
 stage IIB, 284-285  
 stage III, 285-286  
 stage IV, 286  
 staging of, 278-280  
 survival in, 279, 280
- Myelodysplasia, 87  
 as transplantation complication, 93
- Myeloma, progenitor cell transplant in, 2
- N-(phosphonacetyl)-L-aspartic acid, fluorouracil plus, 594
- Nasal cavity lymphoma, 342-343
- Neck, *see* Head and neck lymphoma
- Nerve growth factor, 410
- Nerves, autonomic, of pelvis, 508
- Neuroendocrine differentiation, in prostate cancer, 400-401
- NHL, *see* Non-Hodgkin's lymphoma

- Nilutamide, in prostate cancer, 164  
 NKX3.1, 402  
 Non-Hodgkin's lymphoma, 88  
   combination chemotherapy in, 87-88  
   cyclophosphamide, carmustine, etoposide regimen in, 90  
   dexamethasone, cisplatin, cytarabine regimen in, 88-89  
   diffuse aggressive, 87-91  
   doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone regimen in, 89-90  
   high-dose transplantation-supported chemotherapy in, 84-98  
   incidence of, 84-85  
   initial management of, transplantation in, 86-87  
   mitoxantrone, cyclophosphamide, vindesine, bleomycin, prednisone regimen in, 89-90  
   natural history of, 85  
   peripheral T-cell, 309  
   progenitor cell transplant in, 2  
   prognostic factors in, 85-86  
   relapsed, transplantation in, 86  
 Nonmyeloblastic transplant, 55  
 Nonspecific cross-reacting antigen, 673  
 Nottingham Health Profile, 692, 694  
 Nuclear matrix, 234-235
- Okadaic acid, 391  
 Oligodeoxyribonucleotide, 599-600  
 Oligoribonucleotide, 599-600  
 Oncovax-P  
   adjuvant in, 442  
   clinical trials of, 443-445  
   immunoenhancing strategies for, 442-443  
   toxicity of, 444  
 One alpha-hydroxyvitamin D<sub>2</sub>, structure of, 221  
 Orchiectomy  
   bilateral, 163  
   cost of, 170  
   studies of, 165-166  
 Orotic acid phosphoribosyltransferase, 606, 607  
 Orzel, current status of, 641  
 Outpatient therapy, autologous stem-cell transplantation as, 78  
 Ovarian cancer, high-dose chemotherapy in, 99-105  
 Oxaliplatin, 613  
   in colon cancer, 552  
   compassionate-use programs for, 649-650  
   continuous infusion, 655-657  
   CPT-11 plus, 657-658  
   fluorouracil synergy with, 647-648  
   irinotecan plus, 657-658  
   mechanism of action of, 647  
   pharmacokinetics of, 648  
   pharmacology of, 648  
   phase I trials of, 649  
   in pretreated advanced colorectal cancer, 650  
   in previously treated colorectal cancer, 649-650  
   raltitrexed plus, 657  
   short infusion of, 656-657  
   toxicities of, 648-649, 650  
   two- to six-hour infusion of, 656-657  
   in untreated colorectal cancer, 650-651
- Oxaliplatin, fluorouracil regimen, in colorectal cancer, 651-657  
 Oxaliplatin, fluorouracil, folinic acid regimen  
   in colorectal cancer, 598, 651-657  
   main grade 3-4 WHO toxicities of, 653  
   in metastatic colorectal cancer, 655  
   phase II trials of, 654-655  
   phase III trials of, 655-657  
   second-line antitumoral activity of, 652  
   in untreated advanced colorectal cancer, 654-655  
 Oxonic acid, 614
- P21 WAF1-CIPI, 387-388  
 p53, 390, 463-464, 672  
   in prostate cancer, 383-384  
   metastatic prostate cancer and, 423  
   wild-type, 463  
 Paclitaxel, 102-103, 240  
   in advanced prostate cancer, 187  
 Paclitaxel, estramustine regimen, in prostate cancer, 433-434  
 Paclitaxel, estramustine, etoposide regimen, in prostate cancer, 434  
 PALA, fluorouracil plus, 594  
 Paranasal sinus lymphoma, 343-344  
 Passive immunotherapy, in prostate cancer, 195-196  
 Patient choice, in prostate cancer, 170  
 Pectin, citrus, 240  
 Pelvic dissection, in colorectal cancer, 507  
 Peptide, 13-mer, phase I trial of, 675-676  
 Performance score, 127  
 Perillyl alcohol, structure of, 218  
 Peripheral blood stem-cell mobilization, 50  
 PET, see Positron emission tomography  
 Peutz-Jeghers syndrome, 491  
   genes of, 479  
 Phenylacetate, 237-238  
 Phenylbutyrate, 237-238  
 Phosphoribosyl transferase, 590  
 Phosphoribosylpyrophosphate, 590, 606  
 Phosphoribosylpyrophosphate transferase, 613-614  
 Photochemotherapy  
   in mycosis fungoides, 281-283  
   in stage IB-IIA mycosis fungoides, 283-284  
   in stage IIB mycosis fungoides, 284-285  
   in stage III mycosis fungoides, 285-286  
   in stage IV mycosis fungoides, 286  
 Phototherapy  
   in mycosis fungoides, 281-283  
   in stage IB-IIA mycosis fungoides, 283-284  
   in stage IIB mycosis fungoides, 284-285  
   in stage III mycosis fungoides, 285-286  
   in stage IV mycosis fungoides, 286  
 Picture archival and communications systems, 158-159  
 Plasmacytoma, cutaneous, 302  
 Platinum, dosing of, 100  
 Pneumonia, lymphocytic interstitial, 309-310  
 Polyethylene glycol, interleukin-2 regimen, in prostate cancer, 195  
 Polyglutamate, 590  
 Polymerase chain reaction  
   differential display, 422-427  
   in minimal residual disease detection, 50-51

- Polyps, colorectal, 489
- Portal vein infusion, of fluorouracil, 550-551
- Positron emission tomography  
in colorectal cancer, 577-583  
with non-FDG radiopharmaceuticals, 581-582
- Poxvirus, 678
- Prednisone  
in mediastinal large cell lymphoma, 254-255  
in testicular lymphoma, 264
- Prednisone, colchicine, melphalan regimen, in amyloidosis, 80-81
- Prednisone, cyclophosphamide, doxorubicin, vincristine, bleomycin regimen, in testicular lymphoma, 264
- Prednisone, doxorubicin, cyclophosphamide, vindesine, bleomycin regimen, in NHL, 89-90
- Prednisone, melphalan regimen, in multiple myeloma, 75
- Prednisone, methotrexate, cyclophosphamide, doxorubicin, vincristine, bleomycin regimen, in mediastinal large cell lymphoma, 254-255
- Prednisone, mitoxantrone, cyclophosphamide, vindesine, bleomycin regimen, in NHL, 89-90
- Prednisone, vincristine regimen, in pulmonary lymphoma, 312
- Prednisone, vincristine, carmustine, melphalan, cyclophosphamide regimen, in multiple myeloma, 76
- Primary cutaneous lymphoma, diagnosis of, 296
- Primary non-Hodgkin's lymphoma of bone  
clinical presentation of, 270  
histological diagnosis of, 270  
pathology of, 270-271  
prognostic factors in, 274  
staging of, 271  
therapy complications in, 273-274  
therapy in, 271-274
- Progenitor cell transplantation  
for adult malignancies, 1-5  
in chronic myelogenous leukemia, 62-66
- ProMACE-CytaBOM regimen, 88
- ProsAure, 145-146
- Prostaglandins, synthesis of, 499-504
- Prostate cancer  
advanced, chemotherapy in, 428-438  
in African American men, 375-381  
amphotropic phase of, targeted therapy for, 371  
androgen receptor alterations in, 386-387  
androgen receptor mutation in, 413  
androgen receptor variations in, 412-415  
androgen receptors and, 401-402, 407-421  
androgen responsiveness in, 414-415  
androgen-independent, markers of, 399-406  
androgen-independent cells in, 413-414  
androgens and, 412-415  
angiogenesis inhibitors in, 223-224  
antigen-specific vaccination in, 197-198  
antisense therapy in, 464  
assessing response in, 175  
bilateral orchiectomy in, 163  
biochemical markers in, response of, 179-180  
biologically insignificant, 141-142  
bone metastases in, 178-179  
C-CAM in, 227-233  
caveolin-1 in, 425-426  
Prostate cancer (*Continued*)  
cell death regulation in, for therapy, 382-391  
chemotherapy of, 185-191  
classification of, 369-374  
clinical T3, 206, 211  
clonal expansion phase of, therapy for, 371-372  
combination chemotherapy in, 187-189  
combined androgen blockade in, 166  
contact length in, 142-143  
curability of, 142-143  
detection of, controversies about, 378-379  
development of, predisposition to, 370-371  
doxorubicin in, 431  
drug development for, 217-226  
early detection in, factors impacting on, 375-376  
early or deferred hormonal therapy in, 169  
early-stage detection of, 140-149  
estramustine in, 431-434  
flavones in, 222-223  
gene therapy for, 455-466  
generating active anti-tumor immunity against, 196-197  
genetic alterations in, 402-403  
heterotopic phase of, therapy for, 372  
high-dose cyclophosphamide in, 430-431  
hormonal therapy in, historical background of, 162-163  
hormone-refractory, 428-429  
immune response to, 193-194  
immune system in, 456  
immunologic approaches to, 439-445  
incidence of, 140, 162, 382-383, 439  
informed decision making in, 379-380  
intermittent hormonal therapy in, 169-170  
introduction to, 139  
liposome-encapsulated drugs in, 436  
localized, response in, 175-176  
locally advanced, 202-216  
measurable disease in, 177-178  
metastasis-related genes in, 422-427  
metastatic, and p53, 423  
mitoxantrone in, 434-435  
molecular alterations associated with, 383  
molecular biology of, 462-464  
monoterpenes in, 218-220  
monotherapy in, 163-169  
monotherapy studies in, 165-166  
multiple response categories in, 181  
neuroendocrine differentiation in, 400-401  
nonspecific immune-enhancing agents in, 194-195  
optimal hormonal therapy for, 162-173  
oral cyclophosphamide in, 430  
palpable stage T1-T2, radiotherapy dose-response of, 156  
patient choice in, 170  
percent free PSA detection of, 145  
prognosis in, and pretreatment PSA levels, 150-152  
prognostic categories in, 151  
progression of, clinical biology of, 370  
PSA density in, 143-144  
PSA specificity in, 143  
quality of life in, 170  
quality-of-life improvement in, 180-181  
radioactive seed implant in, 154-158



- Prostate cancer (*Continued*)
- radiotherapy of, 150-161
  - relapsed, synthetic vaccine in, 448-453
  - research in, for early detection, 380
  - response criteria in, 174-184
  - screening for, African American men and, 375-381
  - self-assessment findings in, 155
  - single-agent chemotherapy in, 187
  - small cell, 189
  - stage D, 163
  - standard therapies for, 369-370
  - suramin in, 435-436
  - systemic, response in, 176-181
  - therapeutic categories in, 372-373
  - therapies in development for, 370
  - treatment cost in, 170
  - tumor vaccine in, 457-459
  - tumor volume in, and curability, 142-143
  - vaccines in, 192-201
  - vectors in, 464-465
  - vitamin D analogs in, 220-222
- Prostate carcinoma-associated glycoprotein complex, 457
- Prostate-specific antigen, 399, 442
- advanced applications of, 140-149
  - age-referenced, 144
  - as response criterion, 175
  - biologically insignificant prostate cancer and, 141-142
  - in clinically localized prostate cancer, 204
  - percent free, 145-146
  - pretreatment, and Gleason score, 156
  - pretreatment levels of, and prognosis, 150-152
  - prognostic prostate cancer categories based on, 151
  - in prostate cancer screening, 140-141
  - volume-referenced, 144
- Prostate-specific antigen assay, 369
- Prostate-specific antigen density, 143-144
- of transition zone, 144-145
- Prostate-specific antigen promoter, 465-466
- Prostate-specific antigen test
- increasing specificity of, 143
  - positive predictive values of, 141
- Prostate-specific membrane antigen, 196, 399, 448, 457
- Prostate stromal epithelial cross-talk, 410
- Prostatectomy
- gene therapy and, 213
  - inadequate local control following, 205
  - prognostic factors for, 157
  - prostate cancer curability and, 142-143
  - radical, cryotherapy and, 212
  - radioactive seed implants v, 157
- Protein kinase, 391, 599-600
- Protein kinase C, 390
- Protein-specific antigen, 448
- PSA, see Prostate-specific antigen
- PSMA promoter, 465-466
- Psoralen
- in mycosis fungoides, 281-283
  - in stage IB-IIA mycosis fungoides, 283-284
  - in stage IIB mycosis fungoides, 284-285
  - in stage III mycosis fungoides, 285-286
  - in stage IV mycosis fungoides, 286
- Pulmonary lymphoma
- BALT type of, 308-310
  - characterization of, 307-308
  - classification of, 308-310
  - clinical features of, 310
  - diagnosis of, 311
  - imaging in, 310-311
  - pathology of, 308-310
  - prognosis in, 311-313
  - staging of, 311
  - treatment of, 311-313
- Pulmonary lymphomatoid granulomatosis, 309
- Purging, role of, 50-51
- PUVA
- in mycosis fungoides, 281-283
  - in stage IB-IIA mycosis fungoides, 283-284
  - in stage IIB mycosis fungoides, 284-285
  - in stage III mycosis fungoides, 285-286
  - in stage IV mycosis fungoides, 286
- QALY, 692, 694
- QL index, in outcome prediction, 694
- QLQ-C30, 693
- QLQ-CR38, 693
- QS21, 449
- Quality of life, 175
- as response criterion, in prostate cancer, 180-181
  - definition of, 691
- Quality of life assessment
- cancer-specific instruments for, 692
  - domain-specific instruments for, 692
  - generic, 692
  - in colorectal cancer, 691-695
  - modular approach to, 692-693
- Radiation
- adjuvant, in colon cancer, 551
  - conventional course of, in rectal cancer, 542-543
  - enhanced sphincter preservation with, 543
  - intensive short-course of, in rectal cancer, 542
  - in testicular lymphoma, 263-264
- Radiation therapy, in primary NHL, of bone, 271-274
- Radioactive seed implant
- prognostic factors for, 157
  - in prostate cancer, 154-158
  - prostatectomy v, 157
- Radiofrequency ablation, for hepatic colorectal metastasis, 520-521
- Radioimmunotherapy, with antigody-targeted isotopes, 685-686
- Radiology, in primary NHL, of bone, 271
- Radionuclide scan, in primary NHL, of bone, 271
- Radiosensitizer, fluorouracil as, 599
- Radiotherapy
- external beam, 151-154, 205-208
  - FDG PET monitoring of, in colorectal cancer, 581
  - future of, in prostate cancer, 158-159
  - hormonal therapy plus, in prostate cancer, 207-208
  - intensity-modulated, 152-153, 158
  - in multiple myeloma, 75

- Radiotherapy (*Continued*)  
  in prostate cancer treatment, 150-161  
  three-dimensional conformal, 152-154
- Raltitrexed, 552  
  fluorouracil plus, 599  
  oxaliplatin plus, 657  
  resistance to, mechanisms of, 609
- ras, 388, 672
- Rb gene, 462-464
- REAL classification, 308  
  in primary thyroid lymphoma, 316
- Recombinant carcinoembryonic antigen vaccinia virus, clinical studies of, 673-674
- Recombinant vaccine, for colon cancer, 672-679
- Rectal cancer  
  adjuvant therapy in, 540-544  
  postoperative approach in, 540-541  
  postoperative combined modality therapy for, 541  
  preoperative approach in, 541-543
- Rectal surgery, autonomic nerve preservation in, 508-509
- Resistance, tumor, to cisplatin, 107
- Response criterion(a)  
  biochemical progression as, 176-177  
  historical perspective of, 174-175  
  metamorphosis of, 181-182  
  overall survival as, 176  
  in prostate cancer, 174-184  
  response duration as, 176-177  
  time to progression as, 176-177  
  time to treatment failure as, 176-177
- Reticulohistiocytoma of dorsum, 300
- Retinoblastoma suppressor gene product, 387
- Reverse-transcriptase polymerase chain reaction, quantitative, 607-608
- Revised European-American Lymphoid Classification, 84-85
- Revised European-American Lymphoma Classification, 308  
  in primary thyroid lymphoma, 316-317
- Ribonucleotide reductase, 590
- Rotterdam Symptom Checklist, 692
- RU486, 409
- S-1, 613, 614  
  antitumor activity of, 615, 616  
  clinical activity of, 644  
  current status of, 641  
  therapeutic selectivity of, 614-615
- S193, 687
- Safingol, 390
- Salivary gland lymphoma, 341-342
- Salvage therapy, high-dose autologous stem-cell-supported chemotherapy as, 107-112
- Sarcoma  
  adult, incidence of, 119  
  high-dose chemotherapy in, 119-130  
  progenitor cell transplant in, 3
- Screening, with carcinoembryonic antigen, 557
- Seminoma, testicular lymphoma v, 262-263
- Sensitivity analysis, 563
- 776C85, current status of, 641
- Sézary syndrome  
  characterization of, 276
- Sézary syndrome (*Continued*)  
  classification of, 278  
  clinical features of, 277  
  clinical staging system in, 279  
  diagnosis of, 277-278  
  emerging novel therapies for, 286-287  
  etiology of, 276-277  
  management of, 280-281  
  prognosis in, 278-280  
  stage IA, 281-283  
  stage IB-IIA, 283-284  
  stage IIB, 284-285  
  stage III, 285-286  
  stage IV, 286  
  staging of, 278-280
- Sharp mesorectal excision, in colorectal cancer, 507-508
- Sickness Impact Profile, 692, 694
- Sigmoidoscopy, for colorectal cancer, 486-487
- Small cell carcinoma, 189
- SN-38  
  chemical structure of, 633  
  pharmacology of, 633
- Soft tissue sarcoma, high-dose chemotherapy in, 119-130
- Sphincter  
  chemoradiation for, 511  
  with radiation, 543
- Standardized uptake value, 578
- Stem cell, peripheral blood v bone marrow source of, 68
- Stem-cell transplantation, 102  
  in chronic lymphocytic leukemia, 48-61  
  prognostic factors for, in acute lymphoblastic leukemia, 9-11
- Stool blood testing  
  mortality reduction due to, 487  
  trials of, 486
- Subcutaneous panniculitic T-cell lymphoma, 298-299
- Suicide gene therapy, 459-462
- Suramin, 179-180, 236-237, 390  
  in prostate cancer, 435-436
- Surgery  
  in colorectal cancer, 505-513  
  hormonal therapy plus, in prostate cancer, 210-212
- Survival, as response criterion, in prostate cancer, 176
- SV40 large T antigen, (s)56
- Syngeneic transplantation  
  in chronic myelogenous leukemia, 63  
  in multiple myeloma, 79
- T-cell costimulation, 677-678
- T-cell lymphoma  
  primary intestinal, 329  
  subcutaneous panniculitic, 298-299
- T-cell receptor, in prostate cancer, 455-456
- TAG-72, 457
- TAP-2, 456
- TAS-1, 613
- Testicular germ cell carcinoma, progenitor cell transplant in, 3
- Testicular lymphoma  
  chemotherapy results in, 264  
  CHOP regimen in, 254-255

- Testicular lymphoma (*Continued*)  
clinical presentation of, 260-261  
CNS prophylaxis in, 265  
contralateral testis prophylaxis in, 265  
diagnosis of, 261  
differential diagnosis of, 262-263  
histologic features of, 262  
incidence of, 259-260  
pathologic features of, 261-262  
primary radiotherapy in, outcome following, 263  
prognosis in, 265-266  
stage distribution in, 261  
staging of, 261  
treatment of, 263-265
- Tetrahydrofolate, 590
- Thiotepa  
in CNS lymphoma, 353  
in sarcoma, 126
- Three-dimensional conformal radiotherapy  
boost technique, 153-154  
in prostate cancer, 152-154
- Thymidine phosphorylase, 613  
following interferon-alpha, 669  
following interferon-beta, 669
- Thymidylate synthase, 590, 607, 613  
fluorouracil-based therapy response and, 612  
for fluoropyrimidine resistance, 607-608  
inhibition by, duration of, 612-613  
levels of, clinical trials based on, 610
- Thyroid lymphoma  
classification of, 316-317  
clinical features of, 317  
diagnosis of, 318  
imaging in, 317-318  
outcomes reported in, 321  
pathology of, 316-317  
prognostic factors in, 319  
staging of, 318-319  
treatment of, 319-322
- Time to progression, as response criterion, 176-177
- Time to treatment failure, as response criterion, 176-177
- TNMB classification, of mycosis fungoides, 278
- TNP 470, 213
- Tomudex, 613, 623-625  
chemical structure of, 624  
clinical activity of, 624-625
- Topoisomerase I inhibitor, pharmacology of, 632-634
- Topoisomerase II, 391
- Topotecan  
chemical structure of, 633  
clinical activity of, 636-637  
pharmacology of, 633
- Total body irradiation, in myeloma, 77-78
- Total mesorectal excision  
in colorectal cancer, 507-508  
results of, 507
- Transanal endoscopic microsurgery, in colorectal cancer, 506
- Transanal excision, in colorectal surgery, 506
- Transforming growth factor alpha, 410
- Transforming growth factor beta, 410
- Transgenic adenocarcinoma of mouse prostate, 194
- Transition-zone volume, in prostate cancer, 144-145
- Transplantation, solid-organ, gastrointestinal lymphoma follow-  
ing, 333
- Transrectal ultrasonography  
positive predictive values of, 141  
in prostate cancer detection, 141
- Transrectal ultrasound-guided brachytherapy, in prostate can-  
cer, 209
- Trimethrexate, 590, 613  
fluorouracil plus, 593
- Tumor, Node, Metastasis, Blood system, in mycosis fungoides  
classification, 278
- Tumor d'emblee, 277
- Tumor resistance, to cisplatin, 107
- Tumor vaccine, 455, 457-459  
in prostate cancer, 457-459
- Tumor-associated antigen, 672-673  
definition of, 456-457  
in colon cancer, 685-686
- Tumor-infiltrating lymphocyte  
in breast, 357  
interleukin-2 regimen, in prostate cancer, 195  
in prostate cancer, 456
- Tumor-infiltrating lymphocyte, cyclophosphamide regimen, in  
prostate cancer, 195
- Tumor-suppressor gene, defective, replacing of, 462-464
- UFT, 613, 614  
leucovorin plus, 616  
metabolic modulation of, 615
- UFT, folinic acid regimen, current status of, 641
- UFT, oral folinic acid regimen, clinical activity of, 643-644
- Ultrasonography, transrectal, 141
- Ultraviolet A  
in mycosis fungoides, 281-283  
in stage IB-IIA mycosis fungoides, 283-284  
in stage IIB mycosis fungoides, 284-285  
in stage III mycosis fungoides, 285-286  
in stage IV mycosis fungoides, 286
- Uracil-phosphoribosyltransferase, 600
- Uracil-tegafur regimen, in colon cancer, 552
- Uridine monophosphate kinase, 606
- Utility, definition of, 562
- Utility measure, definition of, 692
- Vaccine(s)  
in prostate cancer, 440  
liposomal PSA, 442  
point-mutated *ras* peptide, trials of, 675-676  
in prostate cancer, 192-201  
study of, performing, 678  
tumor, see Tumor vaccine
- Vascular endothelial growth factor, 196
- Vector  
adenoviral, 465  
for colon cancer vaccines, 673  
in prostate cancer, 464-465  
targeting, 465-466
- Vinblastine, estramustine regimen, in prostate cancer, 432-433

- Vinblastine, ketoconazole, doxorubicin, estramustine regimen, in advanced prostate cancer, 188
- Vincristine  
in CNS lymphoma, 353-354  
in mediastinal large cell lymphoma, 254-255  
in sarcoma, 128  
in testicular lymphoma, 264
- Vincristine, carmustine, melphalan, cyclophosphamide, prednisone regimen, in multiple myeloma, 76
- Vincristine, cyclophosphamide, doxorubicin, methylprednisolone, in myeloma, 77-78
- Vincristine, cyclophosphamide, doxorubicin, prednisone, bleomycin regimen, in testicular lymphoma, 264
- Vincristine, cyclophosphamide, prednisone regimen, in pulmonary lymphoma, 312
- Vincristine, doxorubicin, dexamethasone regimen, in autologous transplantation, 76-77
- Vincristine, doxorubicin, methylprednisolone, in myeloma, 77-78
- Vincristine, methotrexate, cyclophosphamide, doxorubicin, prednisone, bleomycin regimen, in mediastinal large cell lymphoma, 254-255
- Vindesine, doxorubicin, cyclophosphamide, bleomycin, prednisone regimen, in NHL, 89-90
- Vindesine, mitoxantrone, cyclophosphamide, bleomycin, prednisone regimen, in NHL, 89-90
- Vinorelbine, in advanced prostate cancer, 187
- Vinorelbine, estramustine regimen, in prostate cancer, 433
- Vinorelbine, etoposide, estramustine regimen, in advanced prostate cancer, 188
- Virtual colonoscopy, 571-572
- Vitamin D analogs, in prostate cancer drug development, 220-222
- Waldeyer's ring lymphoma, 339-341
- Watchful waiting, in locally advanced prostate cancer, 205
- Whole body FDG-PET, in hepatic colorectal metastasis, 518-519
- Working Formulation, 308
- Xeloda, *see* Capecitabine
- Xenobiotic metabolism, cyclooxygenase and, 501
- ZD1694, 613, 623-625  
chemical structure of, 624  
clinical antitumor activity of, 624-625
- ZD9331, 626
- Zidovudine, fluorouracil plus, 593